Prodep20 mg

Prodep is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of the following conditions, with evidence strength varying by indication:

Established / Approved Indications

• Major Depressive Disorder (MDD): for the acute and maintenance treatment of major depressive episodes in adults and pediatric patients aged 8 years and older.
• Obsessive-Compulsive Disorder (OCD): for the treatment of obsessions and compulsions in adults and pediatric patients aged 7 years and older.
• Bulimia Nervosa: for the reduction of binge-eating and purging behaviors in adults.
• Panic Disorder: with or without agoraphobia, in adults.
• Premenstrual Dysphoric Disorder (PMDD): for management of PMDD symptoms in women.

Combination-Therapy Indications

• Bipolar I Disorder (Depressive Episodes): in combination with olanzapine, as a specific labeled combination regimen.
• Treatment-Resistant Depression: in combination with olanzapine, for depression that has not responded to at least two separate trials of different antidepressants at adequate dose and duration.

Prodep should only be used for these indications under the supervision of a qualified physician, who will confirm the diagnosis and select the appropriate regimen.

Each capsule/tablet or oral solution unit contains Fluoxetine Hydrochloride equivalent to a specified strength of fluoxetine base (commonly available as 10 mg, 20 mg, or 40 mg fluoxetine, and as an oral solution). Strength and formulation should be confirmed on the product label.

Prodep is a selective serotonin reuptake inhibitor (SSRI), a class of antidepressant medicines that work by increasing the availability of serotonin, a neurotransmitter involved in mood regulation, in the brain. It is chemically unrelated to tricyclic, tetracyclic, or other available antidepressant agents.

Prodep is used to treat several psychiatric conditions including major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It is distinguished among SSRIs by its notably long elimination half-life and that of its active metabolite, norfluoxetine, which has clinical implications for dosing, drug interactions, and discontinuation.

Prodep belongs to the therapeutic class of Selective Serotonin Reuptake Inhibitors (SSRIs), a subclass of antidepressant medications.

Fluoxetine Hydrochloride selectively inhibits the reuptake of serotonin (5-hydroxytryptamine) at the presynaptic neuron, increasing the concentration of serotonin available in the synaptic cleft and enhancing serotonergic neurotransmission. It has minimal effect on the reuptake of norepinephrine or dopamine and has weak affinity for muscarinic, histaminergic, and alpha-adrenergic receptors, which accounts for its relatively favorable side-effect profile compared with older antidepressants.

Pharmacokinetics: Fluoxetine Hydrochloride is well absorbed orally, undergoes hepatic metabolism (primarily via CYP2D6) to its active metabolite norfluoxetine, and is a potent inhibitor of the CYP2D6 enzyme itself. It has a long elimination half-life of approximately 4 to 6 days (fluoxetine) and 4 to 16 days (norfluoxetine) with chronic dosing, which is substantially longer than most other SSRIs. This means steady-state is reached slowly, and drug effects and interactions can persist for several weeks after the last dose is taken.

Prodep is administered orally, once daily (typically in the morning) or divided into two doses (morning and midday) if higher doses cause nausea or insomnia. It can be taken with or without food. The oral solution should be diluted or measured as directed on the product label. Consistency in the timing of daily doses helps maintain stable drug levels.

Prodep has several clinically significant drug interactions:

• Monoamine Oxidase Inhibitors (MAOIs): Concomitant use, or use within 14 days of stopping an MAOI, is contraindicated due to a serious risk of serotonin syndrome (a potentially life-threatening reaction). At least 5 weeks should elapse after stopping Prodep before starting an MAOI, due to its long half-life.
• Pimozide and Thioridazine: Contraindicated in combination with Prodep because CYP2D6 inhibition by Prodep raises levels of these drugs, increasing the risk of QT-interval prolongation and serious cardiac arrhythmia.
• Other Serotonergic Drugs: Concurrent use with triptans, other SSRIs/SNRIs, tramadol, lithium, or St. John's Wort increases the risk of serotonin syndrome; combinations should be used cautiously and only under close medical supervision.
• Warfarin and other Anticoagulants: Prodep may potentiate the effect of warfarin, increasing bleeding risk; closer monitoring of coagulation status is advised when co-administered.
• NSAIDs and Aspirin: Concurrent use with Prodep increases the risk of gastrointestinal bleeding due to combined effects on platelet function and gastric mucosa.
• CYP2D6 Substrates (including Tamoxifen): Prodep is a potent inhibitor of CYP2D6 and can significantly increase plasma concentrations of drugs metabolized by this enzyme (e.g., tricyclic antidepressants, flecainide, propafenone). Notably, co-administration with tamoxifen may reduce the concentration of tamoxifen's active metabolite (endoxifen), potentially reducing tamoxifen's effectiveness; concurrent use should generally be avoided.

Always inform your physician or pharmacist of all medicines, supplements, and herbal products being used before starting Prodep.

Common and clinically important side effects of Prodep include:

• Very common/common: nausea, headache, insomnia, somnolence, nervousness/anxiety (particularly early in treatment), diarrhea, dry mouth, excessive sweating, tremor, decreased appetite, and sexual dysfunction (decreased libido, delayed ejaculation, anorgasmia).
• Weight changes: weight loss is more common with short-term use; long-term use has been associated with weight changes in either direction.
• Serious but less common: serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle rigidity), abnormal bleeding, activation of mania/hypomania in patients with bipolar disorder, seizures, angle-closure glaucoma, hyponatremia (particularly in elderly patients), and allergic reactions/rash.
• Important safety warning: Prodep, like other antidepressants, carries an increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24), particularly during the first few months of treatment or after dose changes. Patients of all ages should be monitored closely for worsening depression, unusual changes in behavior, or emergence of suicidal thoughts.

Because Prodep and its active metabolite have a long half-life, side effects and interactions may take longer to appear or resolve compared with other SSRIs.

Pregnancy: Prodep should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus. Use of SSRIs, including Prodep, in the third trimester has been associated with a poor neonatal adaptation syndrome (respiratory distress, feeding difficulty, jitteriness, or irritability in the newborn) in some infants; some studies have also suggested a possible small increased risk of persistent pulmonary hypertension of the newborn with late-pregnancy SSRI exposure. Discontinuation of an established antidepressant should not be undertaken without consulting a physician, as untreated depression itself carries risks in pregnancy.

Lactation: Prodep and its active metabolite are excreted in human breast milk. Because of the potential for adverse effects on the nursing infant, a decision should be made by the physician whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the medicine to the mother. Use only under close medical supervision if breastfeeding.

Boxed Warning - Suicidality Risk: Antidepressants, including Prodep, increase the risk of suicidal thinking and behavior in children, adolescents, and young adults compared with placebo. Close monitoring for clinical worsening and emergence of suicidal thoughts is essential, especially during the first few months of therapy and after dose changes.

Other precautions with Prodep:

• Serotonin Syndrome: risk increases with concomitant serotonergic drugs (see Interactions); watch for agitation, tremor, hyperthermia, and autonomic instability.
• Activation of Mania/Hypomania: screen for bipolar disorder before starting; Prodep should be used with caution, generally with a mood stabilizer, in patients with a history of mania.
• Abrupt Discontinuation: although discontinuation symptoms are generally milder with Prodep due to its long half-life, gradual dose tapering under physician guidance is recommended after prolonged treatment rather than stopping suddenly.
• Abnormal Bleeding: Prodep may impair platelet aggregation and increase bleeding risk, especially when combined with NSAIDs, aspirin, or anticoagulants.
• Hyponatremia: has been reported, particularly in elderly patients and those on diuretics; monitor for confusion, headache, or lethargy.
• Angle-Closure Glaucoma: pupillary dilation from Prodep may trigger an attack in patients with anatomically narrow angles.
• Seizures: use with caution in patients with a seizure disorder.
• Use caution when driving or operating machinery until the individual effect of Prodep on alertness and coordination is known.

Overdose of Prodep may cause nausea, vomiting, seizures, agitation, restlessness, tachycardia, and, rarely, serotonin syndrome, particularly if taken with other serotonergic agents. Suspected overdose is a medical emergency.

In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to induce vomiting or manage the situation at home. Treatment in a hospital setting is generally supportive, based on the patient's clinical presentation; there is no specific antidote.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Pediatric Use: Prodep is approved for MDD in patients 8 years and older and for OCD in patients 7 years and older. Safety and efficacy for other indications (bulimia nervosa, panic disorder, PMDD, bipolar depression/treatment-resistant depression in combination with olanzapine) have not been established in pediatric patients. Growth and weight should be monitored during long-term pediatric treatment. See Precautions and Warnings for the suicidality risk in this age group.

Geriatric Use: No specific dosage adjustment is generally required based on age alone, but elderly patients may be more susceptible to hyponatremia and should be monitored accordingly; a lower or less frequent dose may be considered in frail elderly patients.

Renal Impairment: No dosage adjustment is typically required in mild-to-moderate renal impairment; caution is advised in severe renal impairment.

Hepatic Impairment: A lower dose or less frequent dosing schedule of Prodep should be used, as clearance is reduced (see Dosage and Administration).

Duration of treatment with Prodep is individualized by the treating physician based on indication and response. Acute depressive or OCD episodes are typically treated for at least 6-8 weeks to assess response, with continued maintenance therapy for several months to years to prevent relapse, as determined by the prescriber. Treatment should not be stopped abruptly without medical advice.

Selective Serotonin Reuptake Inhibitor (SSRI); Antidepressant

Fluoxetine Hydrochloride works by selectively inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin availability in the synaptic cleft and enhancing serotonergic neurotransmission, which is believed to underlie its antidepressant, anti-obsessional, and anti-panic effects.

C

Prodep is approved for use in pediatric patients for two specific indications: Major Depressive Disorder (age 8 years and older) and Obsessive-Compulsive Disorder (age 7 years and older). Dosing in children and adolescents is generally initiated at a lower dose than in adults and titrated gradually by the physician based on body weight, clinical response, and tolerability.

Safety and efficacy of Prodep have not been established in pediatric patients for bulimia nervosa, panic disorder, premenstrual dysphoric disorder, or bipolar depression/treatment-resistant depression (combination with olanzapine). All pediatric and adolescent patients started on Prodep should be closely monitored for worsening depression and emergence of suicidal thoughts, particularly during the initial weeks of therapy.